In a report released yesterday, Stephen Willey from Stifel Nicolaus reiterated a Hold rating on Ionis Pharmaceuticals Inc (NASDAQ: IONS), with a price target of $48. The company’s shares closed yesterday at $43.65. According to TipRanks.com, Willey is a 5-star